Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.

Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.

2.

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.

Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S.

Cancer Sci. 2017 Jan;108(1):53-60. doi: 10.1111/cas.13111. Epub 2016 Dec 30.

3.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W.

Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5.

4.

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.

Juchum M, Günther M, Laufer SA.

Drug Resist Updat. 2015 May;20:12-28. doi: 10.1016/j.drup.2015.05.002. Epub 2015 May 12. Review.

PMID:
26021435
5.

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY.

Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.

PMID:
27450722
6.

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.

Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM, Tran PT, Burns TF.

Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.

7.

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.

Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, Oguni S, Niki T, Miyagi Y.

Lab Invest. 2013 Oct;93(10):1137-46. doi: 10.1038/labinvest.2013.102. Epub 2013 Aug 12.

8.

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG.

Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2.

9.

The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.

Takahashi Y, Sheridan P, Niida A, Sawada G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y, Hase K, Kusunoki M, Kudo S, Watanabe M, Yamada K, Sugihara K, Yamamoto H, Suzuki A, Doki Y, Miyano S, Mori M, Mimori K.

Ann Oncol. 2015 May;26(5):935-42. doi: 10.1093/annonc/mdv034. Epub 2015 Jan 28.

PMID:
25632068
10.

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.

Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U.

Mol Cell Proteomics. 2017 May;16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22.

11.

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M.

JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066. No abstract available.

12.

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY.

Oncotarget. 2016 Mar 15;7(11):12404-13. doi: 10.18632/oncotarget.7189.

13.

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, Vasanji A, Flask CA, Halmos B, Koon H, Ma PC.

Cancer Res. 2011 Jul 1;71(13):4494-505. doi: 10.1158/0008-5472.CAN-10-2668. Epub 2011 May 9.

14.

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ.

Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.

15.

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.

Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW.

Sci Rep. 2018 Jan 10;8(1):271. doi: 10.1038/s41598-017-18527-z.

16.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

17.

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.

Dos Santos EO, Carneiro-Lobo TC, Aoki MN, Levantini E, Bassères DS.

Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.

18.

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.

Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.

PMID:
30952716
19.

Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.

Huang KY, Kao SH, Wang WL, Chen CY, Hsiao TH, Salunke SB, Chen JJ, Su KY, Yang SC, Hong TM, Chen CS, Yang PC.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):753-66. doi: 10.1164/rccm.201502-0250OC.

PMID:
26583948
20.

Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.

Xie Y, Zhu S, Zhong M, Yang M, Sun X, Liu J, Kroemer G, Lotze M, Zeh HJ 3rd, Kang R, Tang D.

Gastroenterology. 2017 Nov;153(5):1429-1443.e5. doi: 10.1053/j.gastro.2017.07.036. Epub 2017 Jul 29.

Supplemental Content

Support Center